๐Ÿ‡ฆ๐Ÿ‡บAustralia

TGA Non-Compliance Penalties

2 verified sources

Definition

Clinical trial design and patient recruitment must comply with TGA regulations requiring notification and HREC ethics approval. Non-compliance or delays result in enforceable undertakings, fines, or trial halts, creating financial losses from rework and lost timelines.

Key Findings

  • Financial Impact: AUD 50,000 - 500,000 per violation (civil penalties up to 5,000 penalty units at AUD 313/unit); 20-40% trial budget overrun from delays.
  • Frequency: Per non-compliant trial; high risk in recruitment ethics breaches.
  • Root Cause: Manual handling of complex ethics submissions and patient consent processes prone to errors.

Why This Matters

The Pitch: Biotechnology players in Australia ๐Ÿ‡ฆ๐Ÿ‡บ waste AUD 100,000+ per delayed trial on redesign and penalties. Automation of trial design compliance eliminates this risk.

Affected Stakeholders

Clinical Operations Manager, Regulatory Affairs Specialist, Trial Sponsor

Deep Analysis (Premium)

Financial Impact

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Current Workarounds

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Get Solutions for This Problem

Full report with actionable solutions

$99$39
  • Solutions for this specific pain
  • Solutions for all 15 industry pains
  • Where to find first clients
  • Pricing & launch costs
Get Solutions Report

Methodology & Sources

Data collected via OSINT from regulatory filings, industry audits, and verified case studies.

Evidence Sources:

Related Business Risks

Request Deep Analysis

๐Ÿ‡ฆ๐Ÿ‡บ Be first to access this market's intelligence